AZ promotes a new chief of drug development

John Patterson (photo) is retiring after seeing "mixed" responses from his stint as chief of development at AstraZeneca. Pharmalot notes Patterson, 61, will be replaced by Anders Ekblom, 54, who takes over at the end of January. Ekblom signed on to work at the pharma giant 15 years ago after working at Sweden's prestigious Karolinska Institutet. He is currently head of global clinical development.

Patterson played a key role in the MedImmune acquisition, helping to build AZ's biotech business around the Maryland developer. But he also saw setbacks for some important drug programs for stroke and diabetes.

- read the story from Pharmalot
-
check out the AstraZeneca release

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.